|Bid||322.20 x 1100|
|Ask||322.30 x 800|
|Day's Range||318.50 - 341.55|
|52 Week Range||65.49 - 497.49|
|Beta (5Y Monthly)||1.49|
|PE Ratio (TTM)||38.30|
|Earnings Date||Nov. 04, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||349.33|
Over the past 10 years, U.S. stocks have delivered outstanding returns for investors. The major stock indices such as the Dow Jones Industrial Average, the NASDAQ Composite, and the S&P 500 have all climbed by more than 200% during this boom period. For example, biotech innovators Axsome Therapeutics (NASDAQ: AXSM) and Moderna (NASDAQ: MRNA), along with electric-car giant Tesla (NASDAQ: TSLA), have all generated well over 1,000% returns on capital for investors in just the past three years.
The company's COVID-19 vaccine has been a massive success, but how much is the underlying technology worth?
Authorization for Moderna's (MRNA) COVID-19 vaccine for ages 12-17 was put on hold Friday in light of concerns over a rare side effect known as myocarditis, or a heart inflammation.